


{"id":51298,"date":"2024-04-24T10:35:39","date_gmt":"2024-04-24T08:35:39","guid":{"rendered":"https:\/\/www.fyb.de\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/"},"modified":"2024-04-24T10:35:39","modified_gmt":"2024-04-24T08:35:39","slug":"kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/","title":{"rendered":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners"},"content":{"rendered":"<p>Starnberg\/ Munich \/ Schin\u00addel\u00adlegi (Switz\u00ader\u00adland) \u2014 K\u00fchne Holding AG has ente\u00adred into a defi\u00adni\u00adtive agree\u00adment to acquire the phar\u00admaceu\u00adti\u00adcal contract manu\u00adfac\u00adtu\u00adrer Aenova Group from the leading inter\u00adna\u00adtio\u00adnal invest\u00adment company BC Part\u00adners. As part of the tran\u00adsac\u00adtion, the funds advi\u00adsed by BC Part\u00adners will reinvest along\u00adside K\u00fchne Holding AG and conti\u00adnue to support Aenova as a mino\u00adrity share\u00adhol\u00adder. The finan\u00adcial terms were not disclosed.<\/p>\n<p>The Aenova Group is one of the worl\u00add\u2019s leading CDMOs (Contract Deve\u00adlo\u00adp\u00adment and Manu\u00adfac\u00adtu\u00adring Orga\u00adniza\u00adti\u00adons) in the phar\u00admaceu\u00adti\u00adcal and health\u00adcare indus\u00adtry. Head\u00adquar\u00adte\u00adred in Starn\u00adberg near Munich, the company employs around 4,000 people at 14 produc\u00adtion sites world\u00adwide and is a one-stop service provi\u00adder for the deve\u00adlo\u00adp\u00adment, produc\u00adtion and pack\u00ada\u00adging of phar\u00admaceu\u00adti\u00adcals for phar\u00admaceu\u00adti\u00adcal compa\u00adnies around the world. Under the owner\u00adship of BC Part\u00adners, the Aenova Group has deve\u00adlo\u00adped into one of the ten largest CDMOs in the world. In 2023, Aenova achie\u00adved record results with pro forma sales of EUR 832 million, an increase of 17% compared to the previous year.<\/p>\n<p>K\u00fchne Holding AG, based in Schin\u00addel\u00adlegi (Switz\u00ader\u00adland), bund\u00adles the busi\u00adness inte\u00adrests of Klaus-Michael K\u00fchne. It has an entre\u00adpre\u00adneu\u00adrial focus, holds a majo\u00adrity stake in K\u00fchne+Nagel Inter\u00adna\u00adtio\u00adnal AG and is the largest single share\u00adhol\u00adder in Hapag-Lloyd AG, Deut\u00adsche Luft\u00adhansa AG and Brenn\u00adtag&nbsp;SE.<\/p>\n<p><strong>Domi\u00adnik de Daniel, CEO of K\u00fchne Holding AG<\/strong>said: \u201cWith this invest\u00adment, we are taking an important stra\u00adte\u00adgic step to add health\u00adcare and phar\u00admaceu\u00adti\u00adcal compa\u00adnies with a strong finan\u00adcial base and long-term growth pros\u00adpects to our invest\u00adment port\u00adfo\u00adlio. Aenova is on a very good path and we look forward to acce\u00adle\u00adra\u00adting this further under our leadership.\u201d<\/p>\n<p>BC Part\u00adners utili\u00adzed both the exten\u00adsive origi\u00adna\u00adtion network of its Hamburg office and its exper\u00adtise in the health\u00adcare sector to seize the oppor\u00adtu\u00adnity to invest in Aenova and acqui\u00adred the company outside of an auction process. Health\u00adcare is one of BC Part\u00adners\u2019 core sectors and its dedi\u00adca\u00adted health\u00adcare invest\u00adment team has inves\u00adted more than \u20ac6 billion in 21 health\u00adcare part\u00adner\u00adships since its inception.<\/p>\n<p><strong>Raymond Svider, Chair\u00adman of BC Part\u00adners<\/strong>added: \u201cIt has been a plea\u00adsure working with Jan and the entire Aenova team. Toge\u00adther, we have posi\u00adtio\u00adned the company as a global leader in contract manu\u00adfac\u00adtu\u00adring and estab\u00adlished a solid foun\u00adda\u00adtion for future growth, with the company now bene\u00adfiting from strong sales momen\u00adtum, a record order back\u00adlog and favorable indus\u00adtry tail\u00adwinds. We are plea\u00adsed that such an important German health\u00adcare company can conti\u00adnue its growth trajec\u00adtory under the stra\u00adte\u00adgic leader\u00adship of K\u00fchne Holding AG. We have a long and successful history of working with fami\u00adlies and foun\u00adders across Europe and look forward to working closely with K\u00fchne Holding AG and Aenova in this next chap\u00adter of the company.\u201d<\/p>\n<p>This tran\u00adsac\u00adtion repres\u00adents another oppor\u00adtu\u00adnity for BC Part\u00adners\u2019 funds to return signi\u00adfi\u00adcant capi\u00adtal to inves\u00adtors. BC Part\u00adners has comple\u00adted nine liqui\u00addity events in the last 12 months, gene\u00adra\u00adting EUR 8 billion in value for funds and co-inves\u00adtors advi\u00adsed by BC Part\u00adners, inclu\u00adding exits of port\u00adfo\u00adlio compa\u00adnies Presi\u00addio, Forno d\u2019Asolo Group, IMA and PetSmart in the last six months alone.<\/p>\n<p>\u201cWith the new owner\u00adship struc\u00adture, we will conti\u00adnue to imple\u00adment our stra\u00adtegy to make Aenova the leading CDMO with market-leading capa\u00adbi\u00adli\u00adties and inno\u00adva\u00adtive specialty tech\u00adno\u00adlo\u00adgies in Europe. With its long-term invest\u00adment hori\u00adzon, K\u00fchne Holding AG is the perfect comple\u00adment for the company to support this stra\u00adtegy. It enables us to conti\u00adnue on the path of opera\u00adtio\u00adnal excel\u00adlence in the conven\u00adtio\u00adnal produc\u00adtion busi\u00adness while buil\u00adding highly sought-after tech\u00adno\u00adlogy plat\u00adforms and deve\u00adlo\u00adp\u00adment services to meet custo\u00admer demand in the future,\u201d empha\u00adsi\u00adzes Jan Kengel\u00adbach, CEO of Aenova since&nbsp;2018.<\/p>\n<p><strong>E3X Part\u00adners<\/strong> (\u201cE3X\u201d) has worked closely with K\u00fchne Holding AG to struc\u00adture and execute the plan\u00adned acqui\u00adsi\u00adtion. Martin Mix, Mana\u00adging Part\u00adner at E3X, an invest\u00adment and advi\u00adsory firm, comm\u00adents: \u201cOur part\u00adner\u00adship with K\u00fchne Holding AG under\u00adlines our stra\u00adte\u00adgic commit\u00adment to brin\u00adging toge\u00adther the right long-term part\u00adners to support Aeno\u00adva\u2019s growth.\u201d Jan-Felix Stolz, Mana\u00adging Part\u00adner at E3X, adds: \u201cAenova has a high stra\u00adte\u00adgic rele\u00advance for the growing Euro\u00adpean phar\u00admaceu\u00adti\u00adcal market and we are exci\u00adted about the company\u2019s prospects.\u201d<\/p>\n<p>- <strong> BC Part\u00adners and Aenova were advi\u00adsed by Jeffe\u00adries, Kirk\u00adland &amp; Ellis, L.E.K. and PwC<\/strong>.<br>\n<strong>- K\u00fchne Holding AG and E3X Part\u00adners were advi\u00adsed by Allen &amp; Overy and&nbsp;EY.<\/strong><\/p>\n<p>The tran\u00adsac\u00adtion is subject to custo\u00admary closing condi\u00adti\u00adons and the appr\u00adoval of the rele\u00advant merger control authorities.<\/p>\n<p><strong>About the Aenova Group<\/strong><\/p>\n<p>The Aenova Group is a leading global contract manu\u00adfac\u00adtu\u00adrer and deve\u00adlo\u00adp\u00adment service provi\u00adder for the phar\u00admaceu\u00adti\u00adcal and health\u00adcare indus\u00adtry. As a one-stop store, Aenova deve\u00adlops, produ\u00adces and packa\u00adges all common dosage forms, product groups and active ingre\u00addi\u00adent clas\u00adses from phar\u00admaceu\u00adti\u00adcals to food supple\u00adments for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low doses, OEB 1 to 5 (Occu\u00adpa\u00adtio\u00adnal Expo\u00adsure Band). Around 4,000 employees at 14 loca\u00adti\u00adons in Europe and the USA contri\u00adbute to the company\u2019s success. Further infor\u00adma\u00adtion can be found at www.aenova-group.com.<\/p>\n<p><strong>About BC Partners<\/strong><\/p>\n<p>BC Part\u00adners is a leading invest\u00adment firm with more than EUR 40 billion in assets under manage\u00adment in the areas of private equity, private debt and real estate stra\u00adte\u00adgies. BC Part\u00adners was foun\u00added in 1986 and has played an active role in the deve\u00adlo\u00adp\u00adment of the Euro\u00adpean buy-out market for over three deca\u00addes. Today, BC Part\u00adners\u2019 inte\u00adgra\u00adted trans\u00adat\u00adlan\u00adtic invest\u00adment teams operate from offices in Europe and North America and are focu\u00adsed on our four core sectors: TMT, Health\u00adcare, Services and Indus\u00adtri\u00adals, and Consu\u00admer. Since its incep\u00adtion, BC Part\u00adners has made over 127 private equity invest\u00adments in compa\u00adnies with a total value of over \u20ac160 billion and is curr\u00adently inves\u00adt\u00ading its eleventh private equity buyout fund. www.bcpartners.com.<\/p>\n<p><strong>About E3X Partners<\/strong><\/p>\n<p>E3X Part\u00adners is an invest\u00adment and advi\u00adsory firm specia\u00adli\u00adzing in long-term part\u00adner\u00adships with invest\u00adment holding compa\u00adnies, family offices and busi\u00adness owners. We offer custo\u00admi\u00adzed capi\u00adtal solu\u00adti\u00adons and stra\u00adte\u00adgic advice in public and private markets with a focus on Europe. Our custo\u00admi\u00adzed services include invest\u00adment sourcing, tran\u00adsac\u00adtion execu\u00adtion, port\u00adfo\u00adlio manage\u00adment, opera\u00adtio\u00adnal value crea\u00adtion and board functions.<\/p>\n<p>E3X Part\u00adners was foun\u00added by Martin Mix and Jan-Felix Stolz and combi\u00adnes exper\u00adtise from the fields of private equity, finan\u00adcial markets and stra\u00adte\u00adgic consul\u00adting. We forge lasting part\u00adner\u00adships based on trust, colla\u00adbo\u00adra\u00adtion and excel\u00adlence to promote sustainable growth and deli\u00adver lasting value to our part\u00adners. www.e3xpartners.com.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Starnberg\/ Munich \/ Schin\u00addel\u00adlegi (Switz\u00ader\u00adland) \u2014 K\u00fchne Holding AG has ente\u00adred into a defi\u00adni\u00adtive agree\u00adment to acquire the phar\u00admaceu\u00adti\u00adcal contract manu\u00adfac\u00adtu\u00adrer Aenova Group from the leading inter\u00adna\u00adtio\u00adnal invest\u00adment company BC Part\u00adners. As part of the tran\u00adsac\u00adtion, the funds advi\u00adsed by BC Part\u00adners will reinvest along\u00adside K\u00fchne Holding AG and conti\u00adnue to support Aenova as&nbsp;a&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":51296,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1365,1367,1368,1369,1372,1377],"tags":[],"class_list":["post-51298","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-private-equity-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant","category-corporate-finance-ma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Starnberg\/ Munich \/ Schin\u00addel\u00adlegi (Switz\u00ader\u00adland) \u2014 K\u00fchne Holding AG has ente\u00adred into a defi\u00adni\u00adtive agree\u00adment to acquire the phar\u00admaceu\u00adti\u00adcal contract manu\u00adfac\u00adtu\u00adrer Aenova Group from the leading inter\u00adna\u00adtio\u00adnal invest\u00adment company BC Part\u00adners. As part of the tran\u00adsac\u00adtion, the funds advi\u00adsed by BC Part\u00adners will reinvest along\u00adside K\u00fchne Holding AG and conti\u00adnue to support Aenova as a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-24T08:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1050\" \/>\n\t<meta property=\"og:image:height\" content=\"755\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners\",\"datePublished\":\"2024-04-24T08:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\"},\"wordCount\":1051,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg\",\"articleSection\":[\"Private equity\",\"Lawyers\/Tax-advisors\/Auditors\",\"Lawyers, tax consultants, auditors\",\"Investors\",\"Consultant\",\"Corporate Finance\/M&amp;A\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\",\"url\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\",\"name\":\"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg\",\"datePublished\":\"2024-04-24T08:35:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg\",\"width\":1050,\"height\":755},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/","og_locale":"en_US","og_type":"article","og_title":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook","og_description":"Starnberg\/ Munich \/ Schin\u00addel\u00adlegi (Switz\u00ader\u00adland) \u2014 K\u00fchne Holding AG has ente\u00adred into a defi\u00adni\u00adtive agree\u00adment to acquire the phar\u00admaceu\u00adti\u00adcal contract manu\u00adfac\u00adtu\u00adrer Aenova Group from the leading inter\u00adna\u00adtio\u00adnal invest\u00adment company BC Part\u00adners. As part of the tran\u00adsac\u00adtion, the funds advi\u00adsed by BC Part\u00adners will reinvest along\u00adside K\u00fchne Holding AG and conti\u00adnue to support Aenova as a [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-04-24T08:35:39+00:00","og_image":[{"width":1050,"height":755,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners","datePublished":"2024-04-24T08:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/"},"wordCount":1051,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg","articleSection":["Private equity","Lawyers\/Tax-advisors\/Auditors","Lawyers, tax consultants, auditors","Investors","Consultant","Corporate Finance\/M&amp;A"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/","url":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/","name":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg","datePublished":"2024-04-24T08:35:39+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/04\/dominik-de-daniel-kuehne-holding-ag-kuehne-e1713947673969.jpeg","width":1050,"height":755},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/kuehne-holding-acquires-pharmaceutical-contract-manufacturer-aenova-from-bc-partners\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"K\u00fchne Holding acquires pharmaceutical contract manufacturer Aenova from BC Partners"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=51298"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51298\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/51296"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=51298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=51298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=51298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}